Kaleido Biosciences Statistics
Total Valuation
Kaleido Biosciences has a market cap or net worth of 43.
| Market Cap | 43 |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Kaleido Biosciences has 42.62 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 42.62M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.05% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.01% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.00 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.43, with a Debt / Equity ratio of 2.05.
| Current Ratio | 1.43 |
| Quick Ratio | 1.33 |
| Debt / Equity | 2.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.28 |
| Interest Coverage | -30.84 |
Financial Efficiency
Return on equity (ROE) is -580.57% and return on invested capital (ROIC) is -148.23%.
| Return on Equity (ROE) | -580.57% |
| Return on Assets (ROA) | -99.93% |
| Return on Capital (ROIC) | -148.23% |
| Revenue Per Employee | 14,526 |
| Profits Per Employee | -1.19M |
| Employee Count | 76 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 37.53 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | 0.00 |
| Relative Strength Index (RSI) | 46.11 |
| Average Volume (20 Days) | 413 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 21.14 |
Income Statement
In the last 12 months, Kaleido Biosciences had revenue of 1.10 million and -90.29 million in losses. Loss per share was -2.16.
| Revenue | 1.10M |
| Gross Profit | -66.70M |
| Operating Income | -87.52M |
| Pretax Income | -90.29M |
| Net Income | -90.29M |
| EBITDA | -85.16M |
| EBIT | -87.52M |
| Loss Per Share | -2.16 |
Balance Sheet
The company has 38.47 million in cash and 21.69 million in debt, giving a net cash position of 16.78 million or 0.39 per share.
| Cash & Cash Equivalents | 38.47M |
| Total Debt | 21.69M |
| Net Cash | 16.78M |
| Net Cash Per Share | 0.39 |
| Equity (Book Value) | 10.61M |
| Book Value Per Share | 0.25 |
| Working Capital | 12.63M |
Cash Flow
In the last 12 months, operating cash flow was -77.09 million and capital expenditures -1.13 million, giving a free cash flow of -78.22 million.
| Operating Cash Flow | -77.09M |
| Capital Expenditures | -1.13M |
| Free Cash Flow | -78.22M |
| FCF Per Share | -1.84 |
Margins
| Gross Margin | n/a |
| Operating Margin | -7,927.72% |
| Pretax Margin | -8,178.26% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Kaleido Biosciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -25.14% |
| Shareholder Yield | -25.14% |
| Earnings Yield | -209,972,093.02% |
| FCF Yield | -181,913,953.49% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Kaleido Biosciences has an Altman Z-Score of -11.21. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -11.21 |
| Piotroski F-Score | n/a |